PTAB Denies Institution of Rituxan® IPRs Because Petitioner Failed to Establish Certain References Were Publicly Available October 23, 2017
Sanofi, Genzyme, and Regeneron Voluntarily Dismiss Dupixent® (Dupilumab) Declaratory Judgment Suit in Massachusetts May 8, 2017
Immunex Files Patent Infringement Suit Over Dupixent® (Dupilumab) and Seeks to Dismiss or Transfer Sanofi and Regeneron’s Prior DJ Complaint April 12, 2017
Sanofi and Regeneron Follow Declaratory Judgment Complaint with an IPR Petition as FDA Approves Dupixent® (dupilumab) March 30, 2017
Sanofi and Regeneron Seek Declaratory Judgment that Dupixent® (Dupilumab) Does Not Infringe Amgen’s Patent March 22, 2017